3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Leukemia
4
Myelodysplastic Syndromes
2
Lymphoma, Non-Hodgkin
2
Leukemia, Myeloid, Acute
2
Hematologic Neoplasms
2
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Neoplasms, Plasma Cell
1
Multiple Myeloma
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, B-Cell
1
Lymphoma
1
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
1
Leukemia, Myeloid
1
Hodgkin Disease
1
Congenital Abnormalities
1
Carcinoma, Hepatocellular
1
Burkitt Lymphoma
1
Blast Crisis
1
Interventions
Sorafenib
29
Nivolumab
15
pembrolizumab
12
Radiosurgery
9
Bevacizumab
9
atezolizumab
7
regorafenib
5
Radiotherapy
5
Fluorouracil
5
Doxorubicin
5
lenvatinib
4
Sunitinib
4
Oxaliplatin
4
Ipilimumab
4
Gemcitabine
4
Ethiodized Oil
4
Erlotinib Hydrochloride
4
Capecitabine
4
TLC 388
3
Radiofrequency Ablation
3
Leucovorin
3
Everolimus
3
Cisplatin
3
Blood Specimen Collection
3
toripalimab
2
phosphomannopentaose sulfate
2
durvalumab
2
cediranib
2
avelumab
2
Tirapazamine
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Carcinoma, Hepatocellular
×
Methylprednisolone Hemisuccinate
×
Clear all
NCT01726465
2013-11-13
MENHIR
Istituto Clinico Humanitas
Phase 2
Terminated
50 enrolled